Year |
Citation |
Score |
2004 |
Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, Makriyannis A, Piomelli D. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proceedings of the National Academy of Sciences of the United States of America. 101: 8756-61. PMID 15138300 DOI: 10.1073/Pnas.0400997101 |
0.442 |
|
2002 |
Goutopoulos A, Makriyannis A. From cannabis to cannabinergics: new therapeutic opportunities. Pharmacology & Therapeutics. 95: 103-17. PMID 12182958 DOI: 10.1016/S0163-7258(02)00250-4 |
0.524 |
|
2001 |
Goutopoulos A, Fan P, Khanolkar AD, Xie XQ, Lin S, Makriyannis A. Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability. Bioorganic & Medicinal Chemistry. 9: 1673-84. PMID 11425567 DOI: 10.1016/S0968-0896(01)00088-8 |
0.538 |
|
2000 |
Lamb RJ, Järbe TU, Makriyannis A, Lin S, Goutopoulos A. Effects of Delta 9-tetrahydrocannabinol, (R)-methanandamide, SR 141716,and d-amphetamine before and during daily Delta 9-tetrahydrocannabinol dosing. European Journal of Pharmacology. 398: 251-8. PMID 10854837 DOI: 10.1016/S0014-2999(00)00318-6 |
0.456 |
|
1999 |
Gifford AN, Bruneus M, Lin S, Goutopoulos A, Makriyannis A, Volkow ND, Gatley SJ. Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374). European Journal of Pharmacology. 383: 9-14. PMID 10556675 DOI: 10.1016/S0014-2999(99)00609-3 |
0.475 |
|
1999 |
Piomelli D, Beltramo M, Glasnapp S, Lin SY, Goutopoulos A, Xie XQ, Makriyannis A. Structural determinants for recognition and translocation by the anandamide transporter. Proceedings of the National Academy of Sciences of the United States of America. 96: 5802-7. PMID 10318965 DOI: 10.1073/pnas.96.10.5802 |
0.411 |
|
1999 |
Lang W, Qin C, Lin S, Khanolkar AD, Goutopoulos A, Fan P, Abouzid K, Meng Z, Biegel D, Makriyannis A. Substrate Specificity and Stereoselectivity of Rat Brain Microsomal Anandamide Amidohydrolase. Journal of Medicinal Chemistry. 42: 1682. PMID 10231226 DOI: 10.1021/jm990139o |
0.38 |
|
1999 |
Lang W, Qin C, Lin S, Khanolkar AD, Goutopoulos A, Fan P, Abouzid K, Meng Z, Biegel D, Makriyannis A. Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. Journal of Medicinal Chemistry. 42: 896-902. PMID 10072686 DOI: 10.1021/Jm980461J |
0.58 |
|
1998 |
Järbe TU, Sheppard R, Lamb RJ, Makriyannis A, Lin S, Goutopoulos A. Effects of delta-9-tetrahydrocannabinol and (R)-methanandamide on open-field behavior in rats. Behavioural Pharmacology. 9: 169-74. PMID 10065936 |
0.445 |
|
1998 |
Järbe TU, Lamb RJ, Makriyannis A, Lin S, Goutopoulos A. Delta9-THC training dose as a determinant for (R)-methanandamide generalization in rats. Psychopharmacology. 140: 519-22. PMID 9888629 DOI: 10.1007/S002130050797 |
0.486 |
|
1998 |
Lin S, Khanolkar AD, Fan P, Goutopoulos A, Qin C, Papahadjis D, Makriyannis A. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. Journal of Medicinal Chemistry. 41: 5353-61. PMID 9876105 DOI: 10.1021/Jm970257G |
0.542 |
|
1998 |
Qin C, Lin S, Lang W, Goutopoulos A, Pavlopoulos S, Mauri F, Makriyannis A. Determination of anandamide amidase activity using ultraviolet-active amine derivatives and reverse-phase high-performance liquid chromatography. Analytical Biochemistry. 261: 8-15. PMID 9683506 DOI: 10.1006/Abio.1998.2713 |
0.479 |
|
1998 |
Papahatjis DP, Kourouli T, Abadji V, Goutopoulos A, Makriyannis A. Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta 8-tetrahydrocannabinols. Journal of Medicinal Chemistry. 41: 1195-200. PMID 9544219 DOI: 10.1021/Jm970277I |
0.473 |
|
Low-probability matches (unlikely to be authored by this person) |
2014 |
Jiang X, Fischer D, Chen X, McKenna SD, Liu H, Sriraman V, Yu HN, Goutopoulos A, Arkinstall S, He X. Evidence for Follicle-stimulating Hormone Receptor as a Functional Trimer. The Journal of Biological Chemistry. 289: 14273-82. PMID 24692546 DOI: 10.1074/Jbc.M114.549592 |
0.275 |
|
2019 |
Xiao Y, Karra S, Goutopoulos A, Morse NT, Zhang S, Dhanabal M, Tian H, Seenisamy J, Jayaadevan J, Caldwell R, Potnick J, Bleich M, Chekler E, Sherer B. Synthesis and SAR development of quinoline analogs as novel P2X7 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. PMID 31031055 DOI: 10.1016/j.bmcl.2019.04.033 |
0.263 |
|
2014 |
Yu HN, Richardson TE, Nataraja S, Fischer DJ, Sriraman V, Jiang X, Bharathi P, Foglesong RJ, Haxell TF, Heasley BH, Jenks M, Li J, Dugas MS, Collis R, Tian H, ... ... Goutopoulos A, et al. Discovery of substituted benzamides as follicle stimulating hormone receptor allosteric modulators. Bioorganic & Medicinal Chemistry Letters. 24: 2168-72. PMID 24685543 DOI: 10.1016/J.Bmcl.2014.03.018 |
0.25 |
|
2021 |
Qiu H, Ali Z, Bender A, Caldwell R, Chen YY, Fang Z, Gardberg A, Glaser N, Goettsche A, Goutopoulos A, Grenningloh R, Hanschke B, Head J, Johnson T, Jones C, et al. Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry. 40: 116163. PMID 33932711 DOI: 10.1016/j.bmc.2021.116163 |
0.211 |
|
2021 |
Qiu H, Ali Z, Bowlan J, Caldwell R, Gardberg A, Glaser N, Goutopoulos A, Head J, Johnson T, Maurer C, Georgi K, Grenningloh R, Fang Z, Morandi F, Rohdich F, et al. Discovery of novel covalent BTK inhibitors with reduced CYP2C8 inhibitory activity. Chemmedchem. PMID 34582626 DOI: 10.1002/cmdc.202100453 |
0.204 |
|
2013 |
Karra S, Xiao Y, Chen X, Liu-Bujalski L, Huck B, Sutton A, Goutopoulos A, Askew B, Josephson K, Jiang X, Shutes A, Shankar V, Noonan T, Garcia-Berrios G, Dong R, et al. SAR and evaluation of novel 5H-benzo[c][1,8]naphthyridin-6-one analogs as Aurora kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 23: 3081-7. PMID 23570792 DOI: 10.1016/j.bmcl.2013.03.008 |
0.188 |
|
2018 |
Qiu H, Caldwell R, Liu-Bujalski L, Goutopoulos A, Jones R, Potnick J, Sherer B, Bender A, Grenningloh R, Xu D, Johnson T, Follis AV, Head J, Morandi F. Discovery of affinity-based probes for Btk occupancy assay. Chemmedchem. PMID 30521698 DOI: 10.1002/Cmdc.201800714 |
0.179 |
|
2018 |
Caldwell R, Liu-Bujalski L, Qiu H, Mochalkin I, Jones R, Neagu C, Goutopoulos A, Grenningloh R, Johnson T, Sherer B, Gardberg A, Follis AV, Morandi F, Head J. Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk. Bioorganic & Medicinal Chemistry Letters. PMID 30290988 DOI: 10.1016/J.Bmcl.2018.09.033 |
0.174 |
|
2021 |
Xiao Y, Huck BR, Lan R, DeSelm L, Chen X, Qiu H, Neagu C, Johnson T, Mochalkin I, Gardberg A, Jiang X, Tian H, Dutt V, Santos D, Head J, ... ... Goutopoulos A, et al. Discovery of 4-Aminopyrimidine Analogs as highly Potent Dual P70S6K/Akt Inhibitors. Bioorganic & Medicinal Chemistry Letters. 128352. PMID 34481987 DOI: 10.1016/j.bmcl.2021.128352 |
0.17 |
|
2018 |
Qiu H, Liu-Bujalski L, Caldwell RD, Viacava Follis A, Gardberg A, Goutopoulos A, Grenningloh R, Head J, Johnson T, Jones CCV, Jones R, Mochalkin I, Morandi F, Neagu C, Potnick J, et al. Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 30243592 DOI: 10.1016/J.Bmcl.2018.09.018 |
0.165 |
|
2019 |
Caldwell R, Qiu H, Askew BC, Bender AT, Brugger N, Camps M, Dhanabal M, Dutt V, Eichhorn T, Gardberg AS, Goutopoulos A, Grenningloh R, Head J, Healey B, Hodous BL, et al. Discovery of Evobrutinib: An Oral, Potent and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. Journal of Medicinal Chemistry. PMID 31368705 DOI: 10.1021/Acs.Jmedchem.9B00794 |
0.165 |
|
2018 |
Qiu H, Liu-Bujalski L, Caldwell RD, Follis AV, Gardberg A, Goutopoulos A, Grenningloh R, Head J, Johnson T, Jones R, Mochalkin I, Morandi F, Neagu C, Sherer B. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit. Bioorganic & Medicinal Chemistry Letters. 28: 2939-2944. PMID 30122225 DOI: 10.1016/J.Bmcl.2018.07.008 |
0.164 |
|
2022 |
Xiao Y, Huck BR, Lan R, DeSelm L, Chen X, Qiu H, Neagu C, Johnson T, Mochalkin I, Gardberg A, Jiang X, Tian H, Dutt V, Santos D, Head J, ... ... Goutopoulos A, et al. Corrigendum to "Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitors" [Bioorgan. Med. Chem. Lett. 50 (2021) 128352]. Bioorganic & Medicinal Chemistry Letters. 128758. PMID 35484006 DOI: 10.1016/j.bmcl.2022.128758 |
0.152 |
|
2010 |
Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S, Burger P, Rumizen MJ, Podar K, Chauhan D, Hideshima T, Munshi NC, Richardson P, Clark A, Ogden J, ... Goutopoulos A, et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. British Journal of Haematology. 149: 537-49. PMID 20331454 DOI: 10.1111/J.1365-2141.2010.08127.X |
0.14 |
|
2021 |
DeSelm L, Huck B, Lan R, Neagu C, Potnick J, Xiao Y, Chen X, Jones R, Richardson TE, Heasley BH, Haxell T, Moore J, Tian H, Georgi K, Rohdich F, ... ... Goutopoulos A, et al. Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers. Journal of Medicinal Chemistry. PMID 34596404 DOI: 10.1021/acs.jmedchem.1c01087 |
0.114 |
|
Hide low-probability matches. |